Format

Send to

Choose Destination
Diabetologia. 2018 Jan;61(1):6-20. doi: 10.1007/s00125-017-4490-1. Epub 2017 Nov 11.

Epigenetics in diabetic nephropathy, immunity and metabolism.

Author information

1
Department of Internal Medicine, Department of Internal Medicine (463), Radboud University Medical Center, Nijmegen, PO Box 9101, 6500 HB, Nijmegen, the Netherlands. Sam.Keating@radboudumc.nl.
2
Department of Internal Medicine, Department of Internal Medicine (463), Radboud University Medical Center, Nijmegen, PO Box 9101, 6500 HB, Nijmegen, the Netherlands.
3
Central Clinical School, Monash University, 99 Commercial Road, Melbourne, VIC, 3004, Australia. sam.el-osta@monash.edu.
4
Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. sam.el-osta@monash.edu.
5
Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China. sam.el-osta@monash.edu.

Abstract

When it comes to the epigenome, there is a fine line between clarity and confusion-walk that line and you will discover another fascinating level of transcription control. With the genetic code representing the cornerstone of rules for information that is encoded to proteins somewhere above the genome level there is a set of rules by which chemical information is also read. These epigenetic modifications show a different side of the genetic code that is diverse and regulated, hence modifying genetic transcription transiently, ranging from short- to long-term alterations. While this complexity brings exquisite control it also poses a formidable challenge to efforts to decode mechanisms underlying complex disease. Recent technological and computational advances have improved unbiased acquisition of epigenomic patterns to improve our understanding of the complex chromatin landscape. Key to resolving distinct chromatin signatures of diabetic complications is the identification of the true physiological targets of regulatory proteins, such as reader proteins that recognise, writer proteins that deposit and eraser proteins that remove specific chemical moieties. But how might a diverse group of proteins regulate the diabetic landscape from an epigenomic perspective? Drawing from an ever-expanding compendium of experimental and clinical studies, this review details the current state-of-play and provides a perspective of chromatin-dependent mechanisms implicated in diabetic complications, with a special focus on diabetic nephropathy. We hypothesise a codified signature of the diabetic epigenome and provide examples of prime candidates for chemical modification. As for the pharmacological control of epigenetic marks, we explore future strategies to expedite and refine the search for clinically relevant discoveries. We also consider the challenges associated with therapeutic strategies targeting epigenetic pathways.

KEYWORDS:

Chromatin; Diabetes; Diabetic complications; Diabetic nephropathy; EWAS; Epigenetics; Histone; Innate immune memory; Vascular

PMID:
29128937
PMCID:
PMC6448927
DOI:
10.1007/s00125-017-4490-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center